Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | F13A1 | P00488 | 2/20 | 0.38 |
| ▸ | TGM2 | P21980 | 2/20 | 0.38 |
| ▸ | TGM1 | P22735 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.36 |
| ▸ | PLK1 | P53350 | 1/20 | 0.35 |
| ▸ | STS | P08842 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15667961 | 1.00 | ESR2 (0.40) | ESR2NR1H2F13A1TGM2TGM1 | |
| SCHEMBL15667982 | 0.86 | HTT (0.34) | — | |
| SCHEMBL17602847 | 0.86 | HTT (0.34) | — | |
| SCHEMBL15668121 | 0.84 | MKNK1 (0.43) | ESR2NR1H2MEN1KMT2ABRD3 | |
| SCHEMBL17602825 | 0.84 | MKNK1 (0.43) | ESR2NR1H2MEN1KMT2ABRD3 | |
| SCHEMBL19773016 | 0.84 | GPR119 (0.37) | ESR2NR1H2F13A1TGM2TGM1 | |
| SCHEMBL15684526 | 0.82 | ESR2 (0.39) | ESR2NR1H2MEN1KMT2ABRD3 | |
| SCHEMBL21369533 | 0.81 | ESR2 (0.43) | ESR2NR1H2MEN1KMT2AMMP13 | |
| SCHEMBL5341383 | 0.81 | ESR2 (0.43) | ESR2NR1H2MEN1KMT2AMMP13 | |
| SCHEMBL5341385 | 0.81 | ESR2 (0.43) | ESR2NR1H2MEN1KMT2AMMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9868717-B2 | Tricyclic sulphonamide compounds and methods of making and using same | ZAFGEN, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868717-B2 | Tricyclic sulphonamide compounds and methods of making and using same | ZAFGEN, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| EP-2925737-B1 | TRICYCLIC COMPOUNDS FOR USE IN THE TREATMENT AND/OR CONTROL OF OBESITY | ZAFGEN INC (US) | 2017-06-14 | — | — | EP | disclosed |
| US-20160083362-A1 | TRICYCLIC SULPHONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083362-A1 | TRICYCLIC SULPHONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | DNPEP, ANPEP, METAP2 | ESR2 2774/4885NR1H2 3531/4885F13A1 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.